Clover Health Investments... (CLOV)

Here is how Clover Health Investments, Corp. (CLOV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Clover Health Investments (CLOV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently bu...

Clover's strong membership growth, rising revenues, and first-half EBITDA profitability highlight its tech-driven Medicare Advantage edge.

Clover Health Investments (CLOV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agre...

While Clover Health's Q2 earnings showed continued member and revenue growth, it dropped 30% since then due to higher medical costs that impacted all MA plan providers. Clover Health still maintains i...

Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.

Clover Health (CLOV) Q2 Sales Up 34%

Clover Health Investments, Corp. (NASDAQ:CLOV ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Andrew Toy - Co-Founder, CEO & Director Peter J. Kuipers - Chief Financi...

Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago.

CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.